Results 1 to 10 of about 323,712 (116)

Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study [PDF]

Biomedicines
Background/Objectives: Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions.
Itai Ghersin, Maya Fischman, Giacomo Calini, Eduard Koifman, Valerio Celentano, Jonathan P. Segal, Orestis Argyriou, Simon D. McLaughlin, Heather Johnson, Matteo Rottoli, Kapil Sahnan, Janindra Warusavitarne, Ailsa L. Hart   +12 more
doaj   +2 more sources

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

Therapeutic Advances in Neurological Disorders, 2020
Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However,
Sinah Engel, Felix Luessi, Aneka Mueller, Rudolf E. Schopf, Frauke Zipp, Stefan Bittner   +5 more
doaj   +2 more sources

Clinical use of anti-TNF therapy and increased risk of infections

Drug, Healthcare and Patient Safety, 2013
Tauseef Ali,1,2 Sindhu Kaitha,2 Sultan Mahmood,2 Abdul Ftesi,3 Jordan Stone,2 Michael S Bronze21OU Physicians Center for Inflammatory Bowel Disease, University of Oklahoma Health Sciences Center, 2Department of Internal Medicine, University of Oklahoma ...
Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS   +5 more
doaj   +2 more sources

Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus [PDF]

BMJ Open Gastroenterology
Background Despite research, there are still controversial areas in the management of Crohn’s disease (CD).Objective To establish practical recommendations on using anti-tumour necrosis factor (TNF) drugs in patients with moderate-to-severe CD.Methods ...
Ignacio Marin-Jimenez, Guillermo Bastida, Daniel Carpio, Fernando Muñoz, Yago González-Lama, Elena Ricart, Daniel Ceballos, Daniel Ginard, Luis Menchen   +8 more
doaj   +2 more sources

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

Frontiers in Immunology, 2022
Anti-tumor necrosis factor (TNF) biological therapy has generally been accepted as a standard therapeutic option in inflammatory bowel disease (IBD) patient who are refractory to steroids or immunomodulators.
Guanglin Cui, Guanglin Cui, Guanglin Cui, Jon Florholmen, Rasmus Goll   +4 more
doaj   +1 more source

Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis

Biomedicines, 2022
Anti-TNF therapy has significantly improved disease control in rheumatoid arthritis, but a fraction of rheumatoid arthritis patients do not respond to anti-TNF therapy or lose response over time.
Gregor Jezernik, Mario Gorenjak, Uroš Potočnik   +2 more
doaj   +1 more source

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis

Heliyon, 2023
Background and objectives: There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy.
Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao   +9 more
doaj   +1 more source

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease

Biomolecules, 2023
Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such ...
Maja Hanić, Frano Vučković, Helena Deriš, Claire Bewshea, Simeng Lin, James R. Goodhand, Tariq Ahmad, Irena Trbojević-Akmačić, Nicholas A. Kennedy, Gordan Lauc, PANTS Consortium   +10 more
doaj   +1 more source

Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study

BMC Gastroenterology, 2022
Background Prevalence of inflammatory bowel disease (IBD) is increasing in China. The EXPLORE study evaluated the incidence and indicators of suboptimal responses to first-line anti-tumor necrosis factor (TNF) in patients with ulcerative colitis (UC) or ...
Ji Li, Zhanju Liu, Pinjin Hu, Zhonghui Wen, Qian Cao, Xiaoping Zou, Yan Chen, Yingde Wang, Jie Zhong, Xizhong Shen, Dirk Demuth, Olga Fadeeva, Li Xie, Jun Chen, Jiaming Qian   +14 more
doaj   +1 more source

Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study [PDF]

The Korean Journal of Internal Medicine, 2020
Background/Aims The optimal timing for initiation of anti-tumor necrosis factor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about the clinical outcomes of early versus late administration of anti-TNF agents, especially in ...
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon   +3 more
doaj   +1 more source